Management of Nonsevere Pneumonia in Military Trainees with the Urinary Antigen Test for Streptococcus pneumoniae: An Innovative Approach to Targeted Therapy
Author(s) -
Guchev Ia,
Victor L. Yu,
A. I. Sinopalnikov,
О И Клочков,
Roman S. Kozlov,
L. Stratchounski
Publication year - 2005
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/429919
Subject(s) - medicine , pneumonia , amoxicillin , mycoplasma pneumoniae , clarithromycin , streptococcus pneumoniae , urinary system , chlamydia , community acquired pneumonia , antibiotics , immunology , microbiology and biotechnology , helicobacter pylori , biology
The drug of choice for treatment of Streptococcus pneumoniae infection is generally a penicillin (including amoxicillin). Targeted therapy is, however, rarely used, because results of definitive diagnostic tests for pneumonia are not available for several days. Thus, broad-spectrum antibiotics are used for empirical treatment of pneumonia to cover both typical and atypical pathogens. Our purpose was to assess the usefulness of a strategy of targeted antimicrobial therapy based on the results of a rapid urinary antigen test for S. pneumoniae.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom